Literature DB >> 16618749

Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo.

Blake A Jacobson1, Michael D Alter, Marian G Kratzke, Sandra P Frizelle, Ying Zhang, Mark S Peterson, Svetlana Avdulov, Riikka P Mohorn, Bryan A Whitson, Peter B Bitterman, Vitaly A Polunovsky, Robert A Kratzke.   

Abstract

Aberrant hyperactivation of the cap-dependent protein synthesis apparatus has been documented in a wide range of solid tumors, including epithelial carcinomas, but causal linkage has only been established in breast carcinoma. In this report, we sought to determine if targeted disruption of deregulated cap-dependent translation abrogates tumorigenicity and enhances cell death in non-small cell lung cancer (NSCLC). NSCLC cell lines were stably transfected with either wild-type 4E-BP1 (HA-4E-BP1) or the dominant-active mutant 4E-BP1(A37/A46) (HA-TTAA). Transfected NSCLC cells with enhanced translational repression showed pronounced cell death following treatment with gemcitabine. In addition, transfected HA-TTAA and HA-4E-BP1wt proteins suppressed growth in a cloning efficiency assay. NSCLC cells transduced with HA-TTAA also show decreased tumorigenicity in xenograft models. Xenograft tumors expressing HA-TTAA were significantly smaller than control tumors. This work shows that hyperactivation of the translational machinery is necessary for maintenance of the malignant phenotype in NSCLC, identifies the molecular strategy used to activate translation, and supports the development of lung cancer therapies that directly target the cap-dependent translation initiation complex.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16618749     DOI: 10.1158/0008-5472.CAN-05-2879

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation.

Authors:  Manish R Patel; Ahad A Sadiq; Joe Jay-Dixon; Tanawat Jirakulaporn; Blake A Jacobson; Faris Farassati; Peter B Bitterman; Robert A Kratzke
Journal:  Int J Oncol       Date:  2011-11-04       Impact factor: 5.650

2.  Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.

Authors:  Manish R Patel; Blake A Jacobson; Holly Belgum; Ahmad Raza; Ahad Sadiq; Jeremy Drees; Hengbing Wang; Joseph Jay-Dixon; Ryan Etchison; Mark J Federspiel; Stephen J Russell; Robert A Kratzke
Journal:  J Thorac Oncol       Date:  2014-08       Impact factor: 15.609

Review 3.  Targeting eukaryotic protein translation in mesothelioma.

Authors:  Robert A Kratzke
Journal:  Transl Lung Cancer Res       Date:  2017-06

4.  New insights into 4E-BP1-regulated translation in cancer progression and metastasis.

Authors:  Jun Wang; Qing Ye; Qing-Bai She
Journal:  Cancer Cell Microenviron       Date:  2014

5.  Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation.

Authors:  Oshrat Attar-Schneider; Victoria Zismanov; Liat Drucker; Maya Gottfried
Journal:  Tumour Biol       Date:  2015-10-30

6.  mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells.

Authors:  Stacia L Koppenhafer; Kelli L Goss; William W Terry; David J Gordon
Journal:  Mol Cancer Ther       Date:  2018-10-03       Impact factor: 6.261

7.  Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research.

Authors:  Antonello Punturieri; Eva Szabo; Thomas L Croxton; Steven D Shapiro; Steven M Dubinett
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

8.  Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival.

Authors:  Bryan C Barnhart; Jennifer C Lam; Regina M Young; Peter J Houghton; Brian Keith; M Celeste Simon
Journal:  Cancer Biol Ther       Date:  2008-09-11       Impact factor: 4.742

9.  Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer.

Authors:  Biljana Culjkovic; Katherine L Borden
Journal:  J Oncol       Date:  2009-12-13       Impact factor: 4.375

10.  Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma.

Authors:  B A Jacobson; A De; M G Kratzke; M R Patel; J Jay-Dixon; B A Whitson; A A Sadiq; P B Bitterman; V A Polunovsky; R A Kratzke
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.